<DOC>
	<DOC>NCT02564107</DOC>
	<brief_summary>This study will evaluate the efficacy, safety, and effect on quality of life of oral ibandronate (Bondronat) in participants with breast cancer and metastatic bone disease. The anticipated time on study treatment is 25 weeks, and the target sample size is 50 individuals.</brief_summary>
	<brief_title>A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Females at least 18 years of age Breast cancer Bone metastases Use of bisphosphonates within the last 3 months Prior use of gallium nitrate or metastron Severely impaired renal function Hypocalcemia or primary hyperparathyroidism Central nervous system (CNS) metastases</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>